
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
MFSD10 (solute carrier family 75 member 1) encodes a member of the major facilitator superfamily of membrane transport proteins. The encoded protein is thought to function in the efflux of organic anions, including the non-steroidal anti-inflammatory drugs indomethacin and diclofenac. Its predicted transporter activity suggests a role in cellular movement and clearance of organic compounds.
A human urinary bladder transitional papillary tumor cell line established in 1968 from a recurrent, well-differentiated papillary tumor of a 63-year-old man. The original tumor was classified as clinical stage T2 and histological grade G1 and had been treated previously with gold grains and subsequently with diathermy following recurrence.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_001146069
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?